Yuanhang Wang

Yuanhang Wang

Auto-generated profile, based on publicly available information

Yuanhang Wang

Department of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2024 in The Clinical Respiratory Journal
Verified
Journal Article
Open access
YWYuanhang Wang
Yuanhang Wang
KZKelei Zhao
Kelei Zhao
JZJingjing Zhang
Jingjing Zhang
XYXiaohan Yuan
Xiaohan Yuan
YLYanting Liu
Yanting Liu
MZMin Zhang
Min Zhang
SMARCA4‐deficient undifferentiated tumor (SMARCA4‐UT) in the chest is a high‐grade malignant tumor that grows rapidly and often carries a poor prognosis. Unfortunately, there are currently no effective treatment available until now. Here, we report a case of SMARCA4‐UT in a patient who showed a swift response to a combination treatment of penpulimab, anlotinib, and chemotherapy. A 55‐year‐old man was diagnosed with thoracic SMARCA4‐UT along with metastases to multiple lymph nodes, the pleura, and bones. Immunohistochemical (IHC) testing indicated the absence of PD‐L1 expression in tumor cells. He was given sintilimab and anlotinib as first line treatment. However, a follow‐up chest CT revealed progressive disease (PD) after the first cycle treatment. Subsequently, the second line regimen was modified to etoposide and cisplatin (EP) combined with anlotinib and penpulimab. The effectiveness evaluation revealed partial remission (PR) following two cycles of the second‐line regimen treatment. Notably, the patient's progress‐free survival (PFS) exceeds 7 months and the overall survival up to 12 months. Our case implies that a combination of chemotherapy, anlotinib, and penpulimab might offer a promising therapeutic approach for PD‐L1‐negative thoracic SMARCA4‐UT.

1 January 2024 in Clinical Medicine Insights: Oncology
Verified
Journal Article
Open access
MZMin Zhang
Min Zhang
YWYuanhang Wang
Yuanhang Wang
ZSZhiyuan Song
Zhiyuan Song
YLYimeng Lu
Yimeng Lu
HZHouyu Zhao
Houyu Zhao
YLYanting Liu
Yanting Liu
By modifying immune cells, immunotherapy can activate immune response to establish long-term immune memory and prevent tumor recurrence. However, their effectiveness is largely constricted by the poor immunogenicity, immune escape, and immune tolerance of the tumor. This is related to the characteristics of the tumor itself, such as genome instability and mutation. The combination of various nanocarriers with tumor immunotherapy is beneficial for overcoming the shortcomings of traditional immunotherapy. Nanocarriers coated by cell membranes can extend blood circulation time, improve ability to evade immune clearance, and enhance targeting, thus significantly enhancing the efficacy of immunotherapy and showing great potential in tumor immunotherapy. This article reviews the application research progress of different types of cell membrane–modified nanocarriers in tumor immunotherapy, immunotherapy combination therapy, and tumor vaccines, and provides prospects for future research.